Evidence map›Paper›PMID 26169045›Full record

Trial reportProstate cancer and prostatic diseases2015

A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer.

A J Pantuck, C A Pettaway, R Dreicer, J Corman, A Katz, A Ho, W Aronson, W Clark, G Simmons, D Heber

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Prostate cancer and prostatic diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 64 citations in OpenAlex.

  1. Trial
  2. Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Analytical Validation ofMethods and protocols · 2022
    Article
  10. Article
  11. [Complementary medicine in uro-oncology].Der Urologe. Ausg. A · 2021
    Article
  12. Therapeutic Effects ofJournal of nutrition and metabolism · 2021
    Review
  13. Review
  14. [Complementary medicine in uro-oncology].Der Urologe. Ausg. A · 2020
    Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. 20 years-A retrospective of prostate cancer and prostatic diseases.Prostate cancer and prostatic diseases · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

A J PantuckDepartment of Urology, Institute of Urologic Oncology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
C A PettawayThe University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
R DreicerCleveland Clinic Foundation, Cleveland, OH, USA.
J CormanVirginia Mason Medical Center, Seattle, WA, USA.
A KatzWinthrop University Hospital, Garden City, NY, USA.
A HoWinthrop University Hospital, Garden City, NY, USA.
W Aronson1] Department of Urology, Institute of Urologic Oncology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA [2] VA Medical Center Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
W ClarkAlaska Clinical Research Center, Anchorage, AL, USA.
G SimmonsFive Valleys Urology, Missoula, MT, USA.
D Heber1] Department of Urology, Institute of Urologic Oncology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA [2] Department of Medicine and Clinical Nutrition, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
University of California, Los Angeles · USWinthrop-University Hospital · USAlaska Neurology Center · USCleveland Clinic · USThe University of Texas MD Anderson Cancer Center · USVirginia Mason Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe primary objective of this study was to compare the effects of pomegranate juice on PSA doubling times (PSADT) in subjects with rising PSA levels after primary therapy for prostate cancer.

methodsDouble-blind, placebo-controlled multi-institutional study, evaluated the effects of pomegranate liquid extract on serum PSA levels. The primary end point of this study was change in serum PSADT. Additional secondary and exploratory objectives were to evaluate the safety of pomegranate juice and to determine the interaction of manganese superoxide dismutase (MnSOD) AA genotype and pomegranate treatment on PSADT.

resultsOne-hundred eighty-three eligible subjects were randomly assigned to the active and placebo groups with a ratio of 2:1 (extract N=102; placebo N=64; juice N=17). The majority of adverse events were of moderate or mild grade. Median PSADT increased from 11.1 months at baseline to 15.6 months in the placebo group (P<0.001) compared with an increase from 12.9 months at baseline to 14.5 months in the extract group (P=0.13) and an increase from 12.7 at baseline to 20.3 in the juice group (P=0.004). However, none of these changes were statistically significant between the three groups (P>0.05). Placebo AA patients experienced a 1.8 month change in median PSADT from 10.9 months at baseline to 12.7 months (P=0.22), while extract patients experienced a 12 month change in median PSADT from 13.6 at baseline to 25.6 months (P=0.03).

conclusionsCompared with placebo, pomegranate extract did not significantly prolong PSADT in prostate cancer patients with rising PSA after primary therapy. A significant prolongation in PSADT was observed in both the treatment and placebo arms. Men with the MnSOD AA genotype may represent a group that is more sensitive to the antiproliferative effects of pomegranate on PSADT; however, this finding requires prospective hypothesis testing and validation.

Indexed as

AgedAntineoplastic Agents, PhytogenicCombined Modality TherapyDisease ProgressionHumansLythraceaeMaleMedication AdherenceMiddle AgedNeoplasm GradingNeoplasm StagingPlant ExtractsPolymorphism, Single NucleotideProstate-Specific AntigenProstatic NeoplasmsSuperoxide DismutaseAntineoplastic Agents, PhytogenicPlant ExtractsProstate-Specific AntigenSuperoxide Dismutase

Identifiers

PMID26169045
OpenAlexW863124906

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.